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The academic community has been quite vocal in complain-
ing about inadequate public funding for diabetes research in
Europe [1], and rightly so! The intrinsic and relative lack of
earmarked research funds (as compared with the USA) for
this particular disease area is truly alarming [1], and our
public authorities, both national and international, seem
unwilling to rise to the challenge. But if we want our
strident alarm calls to be seen as constructive criticism rather
than complaints, we must be alert to new opportunities and
support them if appropriate. While intended to address just a
part of a greater problem, and with a relatively modest
budget on the grand scale of things, the Innovative
Medicines Initiative (IMI; for further information see:
http://www.imi-europe.org/, last accessed in June 2007)
may present us with just such an opportunity.
There is growing concern that Europe is lagging behind its
competitors in developing and launching new drugs. This is
due in part to considerable under-funding within a fragmented
environment characteristic of much European biomedical
research [2]. To redress this imbalance, we need closer
collaboration between the public (national governments and
the European Commission) and private (pharmaceutical
companies and small and medium enterprises) sectors, and
much more money on the table. Certainly, any collaboration
between academic and industry research groups must be part
of a package that ensures academic independence and
freedom from domination by the evil empire (‘Big Pharma’
in this particular context). If public funds are involved, as
they will be for the IMI, a robust yet transparent competitive
review process must be in place, and we should be on our
guard to make sure the IMI gets this right. Equally important,
any new initiative of this kind must be creative and dynamic
in order to capture our imagination and—more important still—
imaginative science, and this will involve breaking free from
the stranglehold of Brussels and its cumbersome procedures.
Let us review the plans in light of these expectations, if not
requirements.
To begin with, how did this all come about? The European
Commission invited the Research Directors’ Group of the
European Federation of Pharmaceutical Industries (EFPIA) to
develop a European Strategic Research Agenda. Its task was to
identify bottlenecks in biomedical research and development
(R&D) [2] and to come up with a plan, the IMI, in order to
address them. The goal is to make Europe more competitive,
and to benefit patients. The IMI has four major ‘pillars’:
& Pillar I: improved predictivity of safety evaluation
& Pillar II: improved predictivity of efficacy evaluation
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& Pillar III: knowledge management
& Pillar IV: education and training
Setting aside the appalling bureaucratic language (don’t
shoot the messenger!), Pillar II is broken down into five
disease tracks. Diabetes (the single focus of the ‘metabolic
diseases’ track) is one, alongside cancer, brain disorders,
inflammatory diseases and infectious diseases. An IMI
diabetes workshop was chaired by V. Koivisto, and leading
specialists from all diabetes stakeholders were consulted
[2]. The major research focus for the IMI will be pre-
competitive research, allowing several companies to work
together with academic institutions without the usual
constraints of the competitive phases of R&D. Understand-
ing disease mechanisms will be critical, as will the
validation of surrogate markers. There will be ample scope
for academic groups to get involved. For those of us who
have been campaigning for increased awareness of the
burden of diabetes and the need for increased research
funding in this disease area, it is rewarding to read the
preamble to this part of the Strategic Research Agenda (see
box) in addition to the major aims [2].
The objective is to involve all key stakeholders (phar-
maceutical industry, academic institutions, patients, regu-
lators, major associations and the European Community) in
a collaborative fashion. The proposed budget for the IMI as
a whole is a substantial €2 billion for the period 2007–2013,
even if only a drop in the ocean in the larger context of the
objectives of the Lisbon Summit (which aimed for an R&D
intensity of at least 3% in Europe). Since this is intended as
a generic funding scheme, rising above individual diseases
to address the larger problem of competitiveness in Europe,
the amount of funding available for any particular disease
area, such as diabetes, is small. The budget is to be divided
equally between the European Commission (EC) and
industry (EFPIA members). Accordingly, if the IMI budget
is approved, this will result in a total investment from the
EC of €1 billion. The requested budget for the diabetes
track is €37.7 million annually, for a total of €264 million
for this same 7 year period (again with half of this sum
contributed by the EC and half by industry). In reality then,
if the IMI budget is approved, the EC will spend just €18.9
million annually on diabetes research in this peculiar
context. This is of the same order of magnitude as funding
for diabetes research through existing framework grants
(sixth and seventh Framework programmes [FP6 and FP7]).
The real value to the community will only become apparent
once the infrastructure is in place, as will be discussed
below. Will applying for these new funds from the IMI (and
spending them) be worth the trouble? Will the anticipated
added value for the research community—and ultimately
the patient—enable us to make a meal from the snack (let’s
be kind and not mention crumbs) on the table?
The proposed structure indicates that pharmaceutical
companies will match EC funds ‘in kind’, by providing
R&D resources such as staff, laboratory facilities, materials
and clinical research, but no cash on the table. EC funding
will come from the FP7 budget, and these public funds will
be used exclusively to fund academic IMI research or to
support small and medium enterprises. So far, so good. Our
enthusiasm is tempered by the small print. It is not yet clear
to me from which particular pocket this money will come.
Without a significant and compensatory increase in the FP7
life sciences budget, as requested by the Research Direc-
torate General, we shall be no better off than before if
money intended for diabetes research in existing, conven-
tional FP7 funding instruments is directed towards the IMI.
Furthermore, it is difficult to understand why the requested
€37.7 million annually for metabolic diseases (diabetes),
although more than three times that for ‘infectious
diseases’, is much less than that for each of the three other
disease tracks. This leopard has not changed its spots.
And so it is that I will admit to complaining once again,
even if, as should be apparent if you care to read on, I really
do admire the concept and goals of the IMI. Is diabetes
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research cheaper than brain research (requested budget
€62.3 million annually)? Is there a less urgent need for new
medicines to treat and cure diabetes than inflammatory
diseases (requested budget €60 million annually)? Are the
bottlenecks so much more evident for cancer (€66.7
million)? Facetious as these questions may be, I need an
answer!
Notwithstanding these grumbles, I believe that the IMI is
a bold new initiative that offers exciting opportunities to the
diabetes research community, and is for the possible benefit
of the person with diabetes. Aside from the obvious interest
in seeing increased funding for research in Europe, and
diabetes research in particular (even if on a far smaller scale
than one might have wished), there are other less evident
but very positive aspects to the IMI that are in keeping with
the aspirations of the European Association for the Study of
Diabetes (EASD) and its partner non-profit organisations.
The initiative thus proposes an innovative infrastructure for
public–private collaboration that should foster much closer
ties between academic and industry-based research groups.
Funding of academic research will be competitive and
subject to peer review even if, as mentioned earlier, we
must pay attention to the small print. By EC standards, the
IMI is intended to have an unusual degree of autonomy,
with its own executive office, scientific committee and
board (albeit with equal representation in the first instance
from the EC and EFPIA). My natural fear is that we shall
still be forced to master ‘Brusselspeak’ if we are to
understand anything about the IMI and to participate in its
actions. Will the IMI’s independence allow it to function in
a scientist-friendly fashion, favouring a less bureaucratic
approach than that lamentably familiar to anyone involved
with current FP grants? Ideally, the structure would be
similar to one proposed at the meeting that the EC
Directorate General for Research and EASD organised
together in Brussels in November 2004 (Diabetes: Europe
rising to the research challenge) and designed to support
public–private joint projects through an independent entity.
Success will depend upon close co-operation between the
interested parties: academic researchers and their represen-
tative organisations/associations and industry.
The European Foundation for the Study of Diabetes
(EFSD), the EASD’s Research Foundation, has positioned
itself as one of the leading supporters of European diabetes
research. The EFSD has already committed over €40
million to diabetes research in Europe and its associated
states in the form of innovative partnerships, largely with
industry. This model works and has already fostered closer
co-operation and understanding between our two research
communities. The EASD has also been successful over these
past years in lobbying for increased public funding for
diabetes research, and more specifically from the EC
Framework Programmes. This new activity led to the creation
of EURADIA (Alliance for European Diabetes Research;
http://www.euradia.org/, last accessed in June 2007), a
collaboration between non-governmental organisations
(EASD, Federation of European Nurses in Diabetes [FEND]
International Diabetes Federation Europe [IDF-Europe],
Juvenile Diabetes Research Foundation International
[JDRF] and Primary Care Diabetes Europe [PCD Europe])
and the pharmaceutical industry (AstraZeneca, Eli Lilly,
GlaxoSmithKline, Merck Sharp and Dohme, Novo Nordisk,
Sanofi Aventis, Servier). I believe this alliance to be ideally
placed to play an important role in the IMI metabolic diseases
track, perhaps providing specific help and expertise (notably
from the EASD/EFSD) with calls for applications and peer
review, a view shared by some members of the EFPIA
Research Directors’ group. The IMI also aims to include
patient groups in its infrastructure and process. Non-
governmental organisations with direct links to individuals
with diabetes are members of EURADIA (see above), with a
representative of European diabetes patient associations (IDF-
Europe), a major research foundation largely run and
supported by individuals with type 1 diabetes or parents of
children with this disease (JDRF), and organisations repre-
senting health professionals playing a critical role in the
translation of research output to the front line of diabetes care
(FEND and Primary Care Diabetes Europe [PCDE]).
Enough dreaming, let’s get back to European reality. We
may complain that the IMI budget is woefully inadequate
from all points of view, but we must put it into context. The
IMI is an experiment; it is a radical new departure for the
EC. Given the extraordinary political restraints that govern
EC actions, it is not surprising that the requested budget is
small. Indeed, even this modest budget has raised eye-
brows. Although conceived a few years ago at the request
of the EC, the IMI budget has only just been approved by
the European Competitiveness Council, in other words, by
ministers of the member states. It is already evident that the
roll-out of the programme, once fully approved, will be
progressive, with substantially reduced funding during the
first couple of years. What can members of the EASD and
indeed all European diabetes research stakeholders do to
help? I believe that the IMI deserves their careful
consideration and support. Potentially, there is something
(although admittedly rather little in monetary terms) for
everyone in this initiative, ideally even for individuals with
diabetes. It will be really important to show the EC and the
IMI leadership that the European diabetes research com-
munity is ready for this new challenge. There may be tough
choices to be made regarding how to spend the limited
resources made available initially. Not all disease areas may
be funded right away; as activists, not complainers, we
must see to it that diabetes features among the first.
Is IMI truly a shot in the arm for European diabetes
research? No. But if the experiment results in a focused,
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cost-effective, rational, independent and scientist-friendly
entity, fostering vital links between research communities
and promoting a more competitive Europe, I believe it is
well worth pursuing.
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